LipidBrick - Innovative Cationic Lipids Fuel Next-Gen LNPs for Targeted Oncology and Advanced Cell Therapies

Lipid nanoparticles (LNPs) have shown promising potential in organ selective targeted -Oncology and Gene Modified Cell Therapies; however, the critical challenge lies in fine-tuning their formulation to enhance specificity, efficiency, and safety, to maximize therapeutic outcomes. 

Here, we present a novel approach through the development of lipid nanoparticles (LNPs) derived from our library of Innovative cationic lipids. These LNPs demonstrate expanded extrahepatic biodistribution, improving drug delivery and cellular targeting. This addresses major challenges in cancer treatment for the development of therapeutic vaccines via targeting antigen presenting cells (APCs) and T cells in the spleen, and organ selective oncology treatments via local injection. 

Optimization of LNP formulations around our cationic lipids leads to localized expression without off-target effects unlike commonly used ionizable lipid-based LNPs. In addition, we investigate ex vivo cell engineering, employing LNPs. We highlight the efficacy and versatility of LNPs based on our library of lipids, which enable the transfection of mRNA in different types of immune cells, leading to transient engineering of CAR-T and NK cells. This data suggests that LNP formulations based on our cationic lipids, with the addition of targeting ligands, could also prove effective for the generation of CAR-Ts and NKs in vivo. The data underpinning these applications were collected through a blend of proof-of-concept studies conducted both in vitro and in vivo, aimed at evaluating the efficacy and safety of imidazolium lipid-based LNP systems.Molecular assays were employed to monitor biodistribution and cellular uptake, offering real-world insights with an emphasis on safety and dosage optimization